The Case for Waiting on Moderna Is About Revenue, Not the Science

Moderna's oncology pipeline has been clinically de-risked, but current products still generate limited revenue relative to its valuation. The next earnings report must show that the commercial base is stabilizing.
The strongest reason to wait on Moderna shares is not doubt about the melanoma result. It is the gap between a promising oncology pipeline and the revenue produced by today's business.
Moderna generated $2.21 billion of revenue in the twelve months through June 2026, far below the $22.3 billion produced during the comparable pandemic-era period in 2022. The company remained loss-making, so investors cannot rely on a conventional earnings multiple. In mid-October, the stock traded at more than 40 times trailing sales after a several-hundred-percent rally.
The commercial base is beginning to recover. Revenue grew from a year earlier in each of the first two quarters of 2026, and management expected full-year growth of as much as 10%. Its newer COVID shot, mNEXSPIKE, captured about 24% of the U.S. retail COVID vaccine market in its first season, according to the company. Most annual vaccine revenue still arrives in the second half, which makes the third quarter especially important.
Products beyond COVID have not yet changed the income statement. The RSV vaccine mRESVIA generated only $8 million in 2025, although a European procurement contract covers up to 24 million doses. The combined flu and COVID vaccine mCOMBRIAX is approved in the European Union but is scheduled for a 2027 launch and is excluded from the 2026 forecast.
Intismeran could eventually reshape Moderna, but it remains investigational and profit economics are shared with Merck. The positive Phase 3 melanoma result improved the program's probability of approval; it did not create current product revenue.
The November 6 earnings report therefore has two jobs. It must show that seasonal vaccine sales are supporting management's annual outlook, and it must preserve enough cash to fund a broad late-stage pipeline. The company expects to end 2026 with $4.7 billion to $5.2 billion of cash and investments.
Waiting is a position on timing, not necessarily on scientific quality. Investors can believe the cancer program is valuable while requiring proof that the existing franchise can slow cash burn before the oncology opportunity becomes commercial.
Continue your MRK research
Related News
Moderna's Melanoma Data Must Justify a Rally Analysts Do Not
Moderna rallied ahead of full Phase 3 melanoma data due Oct. 24, even as Goldman Sachs kept a Neutral rating and set a target well below the share price.
Biotech Catalysts Put Moderna and Achieve Life Sciences in Focus
A dense clinical calendar gives investors several binary events, led by Moderna and Merck’s melanoma program and Achieve Life Sciences’ response to an FDA manufacturing rejection.
Mastercard’s Record Run Raises the Bar for October Earnings
Mastercard enters its October 29 report after strong second-quarter growth, leaving investors focused on cross-border volume, service revenue and whether margins can absorb continued investment.
FMC’s Guidance Collapse Signals a Channel Reset, Not a Normal Miss
FMC cut third-quarter revenue expectations to $65 million to $125 million and forecast a steep adjusted EBITDA loss as it discounts inventory and changes U.S. pricing.
RTX's Pratt Sales Rise 16% Even as New-Engine Mix Weighs on Growth
Pratt & Whitney's second-quarter sales rose 16%, but commercial original-equipment revenue fell as engine mix and repair demand redirected parts. RTX's next report should show whether service recovery and new deliveries can advance together.
Tesla, Meta and RTX Earnings Put AI Spending and Industrial Demand to the Test
A concentrated earnings calendar will test two market concerns at once: whether heavy AI spending is producing returns and whether industrial and consumer demand can withstand higher financing costs after a bruising week for technology shares.














Latest comments